Citigroup Maintains Neutral on Arvinas, Lowers Price Target to $19
ARVNMarch 7, 2025
Read more →These Analysts Revise Their Forecasts On Arvinas After Q4 Results
ARVNFebruary 12, 2025
Read more →Oppenheimer Maintains Outperform on Arvinas, Raises Price Target to $45
ARVNFebruary 12, 2025
Read more →BMO Capital Reiterates Outperform on Arvinas, Lowers Price Target to $82
ARVNFebruary 12, 2025
Read more →Guggenheim Reiterates Buy on Arvinas, Maintains $57 Price Target
ARVNFebruary 12, 2025
Read more →Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday
ARVNFebruary 12, 2025
Read more →Stifel Maintains Buy on Arvinas, Lowers Price Target to $51
ARVNFebruary 12, 2025
Read more →Arvinas Announced Updated Guidance For The Planned First- And Second-line Combination Trials For Vepdegestrant For Locally Advanced Or Metastatic Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
ARVNJanuary 10, 2025
Read more →Unveiling 4 Analyst Insights On Arvinas
ARVNNovember 20, 2024
Read more →BMO Capital Maintains Outperform on Arvinas, Lowers Price Target to $88
ARVNNovember 20, 2024
Read more →Stephens & Co. Initiates Coverage On Arvinas with Overweight Rating, Announces Price Target of $55
ARVNNovember 18, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
ARVNOctober 31, 2024
Read more →Oppenheimer Maintains Outperform on Arvinas, Lowers Price Target to $40
ARVNOctober 31, 2024
Read more →Analyst Ratings For Arvinas
ARVNMay 17, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
ARVNMay 17, 2024
Read more →Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
ARVNMay 16, 2024
Read more →Arvinas And Pfizer Report Updated Clinical Data From Phase 1b Combination Cohort Evaluating Vepdegestrant
ARVNMay 16, 2024
Read more →Where Arvinas Stands With Analysts
ARVNWithin the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings:
September 9, 2022
Read more →Expert Ratings for Arvinas
ARVNWithin the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings:
September 9, 2022
Read more →Barclays Initiates Coverage On Arvinas with Overweight Rating, Announces Price Target of $90
ARVNSeptember 9, 2022
Read more →What 6 Analyst Ratings Have To Say About Arvinas
ARVNOver the past 3 months, 6 analysts have published their opinion on Arvinas (NASDAQ:ARVN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
April 28, 2022
Read more →Credit Suisse Initiates Coverage On Arvinas with Outperform Rating, Announces Price Target of $104
ARVNApril 28, 2022
Read more →